In November 2018, a collaborative forum presented by CIRS and the Utrecht University WHO Collaborating Centre for Pharmaceutical Policy and Regulation brought together regulatory, HTA, industry and academic perspectives with the aim of identifying novel research that is needed to inform new initiatives being proposed or piloted by key stakeholders to ensure that medicines approved through facilitated regulatory pathways will be aligned with the appropriate flexible access schemes.